Telemetric gastrointestinal capsules
This article was originally published in The Gray Sheet
FDA guidance document for device 510(k)s includes patient labeling as one of seven special controls. Patients should be aware of issues of electromagnetic interference and limitations of physical activity, the Nov. 28 guidance states. Given Imaging's M2A capsule, which was approved through the de novo 510(k) process Aug. 1 after initially being designated Class III, can take roughly 24 hours to move through a patient's digestive tract (1"The Gray Sheet" July 30, 2001, p. 14)...
You may also be interested in...
Given Imaging hopes to be the second company to have a product cleared by way of FDA's de novo program this year by proposing to include several cautionary statements in the labeling of its wireless endoscopy diagnostic imaging system.
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.